Comparative Pharmacology
Head-to-head clinical analysis: SODIUM NITROPRUSSIDE versus TRANSDERM NITRO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SODIUM NITROPRUSSIDE versus TRANSDERM NITRO.
SODIUM NITROPRUSSIDE vs TRANSDERM-NITRO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Sodium nitroprusside is a prodrug that releases nitric oxide (NO) in vascular smooth muscle cells, activating guanylate cyclase and increasing cGMP, leading to vasodilation of both arterial and venous vessels.
Nitroglycerin is converted to nitric oxide (NO), which activates guanylate cyclase, increasing cGMP in vascular smooth muscle, leading to vasodilation.
Intravenous infusion: Initial 0.3-0.5 mcg/kg/min; titrate up to 10 mcg/kg/min, maximum 10 mcg/kg/min for up to 10 minutes. Usual therapeutic dose: 3 mcg/kg/min. Max cumulative dose: 3.5 mg/kg.
Initial dose 0.2-0.4 mg/hour transdermally once daily. Titrate to 0.4-0.8 mg/hour. Maximum 0.8 mg/hour.
None Documented
None Documented
Sodium nitroprusside itself has a half-life of approximately 2 minutes (converted to cyanide in erythrocytes); the metabolite thiocyanate has a terminal half-life of 2.7-7 days (prolonged in renal impairment, requiring monitoring)
Terminal elimination half-life is approximately 1-4 minutes after IV administration due to rapid metabolism. After transdermal application, the apparent half-life is 3-4 hours due to continued absorption from the skin depot, resulting in a prolonged clinical effect.
Renal: approximately 75% as thiocyanate (metabolite) with 25% unchanged; biliary/fecal: minimal (<5%)
Renal (primarily) and biliary; ~60-80% of the dose is excreted renally as metabolites, with <1% unchanged. Fecal excretion accounts for ~10-20%.
Category C
Category C
Vasodilator
Vasodilator